{"id":"rifampicin-r","safety":{"commonSideEffects":[{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"common","effect":"Orange discoloration of body fluids"},{"rate":"1-5","effect":"Rash"},{"rate":"1-3","effect":"Gastrointestinal upset"},{"rate":"common","effect":"Drug interactions (enzyme induction)"},{"rate":"<1","effect":"Thrombocytopenia"},{"rate":"1-2","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL374478","moleculeType":"Small molecule","molecularWeight":"822.95"},"_dailymed":{"setId":"6dd0e7ca-f136-4d68-9c44-5a729eda0cec","title":"RIFAMPIN (RIFAMPICIN) POWDER [EVEREEN SHANGHAI BIOTECHNOLOGY LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampicin binds to the β-subunit of bacterial RNA polymerase II, blocking the path of elongating RNA and preventing transcription initiation. This mechanism is highly selective for bacterial RNA polymerase and has minimal effect on eukaryotic RNA polymerases, making it effective as an antibiotic. It is bactericidal and works against a broad spectrum of gram-positive and gram-negative bacteria.","oneSentence":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:00.371Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (drug-susceptible and drug-resistant)"},{"name":"Leprosy"},{"name":"Atypical mycobacterial infections (MAC, M. marinum)"},{"name":"Brucellosis"},{"name":"Legionellosis"},{"name":"Endocarditis prophylaxis"}]},"trialDetails":[{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT07467252","phase":"PHASE2","title":"AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT","status":"NOT_YET_RECRUITING","sponsor":"Ministry of Health, Saudi Arabia","startDate":"2026-09","conditions":"Pulmonary Tuberculosis","enrollment":200},{"nctId":"NCT07440160","phase":"NA","title":"Digitally Facilitated, Integrated Community and Facility-Based Interventions: The HEART-TB Trial Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arba Minch University","startDate":"2025-07-01","conditions":"Tuberculosis","enrollment":278},{"nctId":"NCT07429760","phase":"NA","title":"Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2025-08-01","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT07303699","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2026-01-03","conditions":"Pulmonary Tuberculosis (TB)","enrollment":80},{"nctId":"NCT07073638","phase":"PHASE2","title":"Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis","status":"RECRUITING","sponsor":"Thirty Respiratory Limited","startDate":"2025-10-13","conditions":"Pulmonary Tuberculoses","enrollment":24},{"nctId":"NCT07313215","phase":"NA","title":"Rifampin-combined Antibiotic Therapy for Staphylococcal PJI","status":"RECRUITING","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2025-11-13","conditions":"Periprosthetic Joint Infection","enrollment":428},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT06905522","phase":"PHASE3","title":"A PAN-USR TB Multi-Center Trial","status":"RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-06-18","conditions":"Pulmonary Tuberculosis","enrollment":610},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT07213765","phase":"PHASE4","title":"Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease","status":"RECRUITING","sponsor":"Bin Cao","startDate":"2025-07-24","conditions":"Mycobacterium Avium Complex Pulmonary Disease","enrollment":188},{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT07163143","phase":"PHASE3","title":"Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2025-11","conditions":"Tuberculosis (TB)","enrollment":784},{"nctId":"NCT07129629","phase":"PHASE2","title":"Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-08-20","conditions":"Tuberculosis, Pulmonary, Drug-Susceptible Pulmonary Tuberculosis","enrollment":45},{"nctId":"NCT07076225","phase":"PHASE3","title":"Ultra-Short Regimen for Elderly DS-TB","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Third People's Hospital","startDate":"2025-07-25","conditions":"Pulmonary Tuberculosis","enrollment":300},{"nctId":"NCT06041919","phase":"PHASE2","title":"Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis","status":"TERMINATED","sponsor":"Thirty Respiratory Limited","startDate":"2023-09-27","conditions":"Rifampicin Susceptible Pulmonary Tuberculosis","enrollment":20},{"nctId":"NCT02875223","phase":"PHASE1","title":"A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas","status":"TERMINATED","sponsor":"Celgene","startDate":"2016-08-31","conditions":"Lymphoma, Non-Hodgkin, Neoplasms","enrollment":75},{"nctId":"NCT04260477","phase":"PHASE3","title":"Novel Triple-dose Tuberculosis Retreatment Regimen","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2021-03-01","conditions":"Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis","enrollment":370},{"nctId":"NCT06727864","phase":"PHASE3","title":"Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial","status":"RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2024-01-01","conditions":"Pulmonary Tuberculosis","enrollment":270},{"nctId":"NCT05971602","phase":"PHASE2","title":"Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Gates Medical Research Institute","startDate":"2023-07-26","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT06058299","phase":"PHASE2","title":"Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Global Alliance for TB Drug Development","startDate":"2023-10-24","conditions":"Pulmonary TB, Pulmonary Tuberculosis, Drug Sensitive Tuberculosis","enrollment":309},{"nctId":"NCT05406453","phase":"NA","title":"Whole Genome Sequencing of Tuberculosis for Disease Control in Madagascar","status":"COMPLETED","sponsor":"Institut Pasteur de Madagascar","startDate":"2022-05-16","conditions":"Tuberculosis","enrollment":98362},{"nctId":"NCT01380080","phase":"PHASE4","title":"REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-10","conditions":"HIV Infection","enrollment":851},{"nctId":"NCT04121195","phase":"PHASE2, PHASE3","title":"Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2020-10-30","conditions":"HIV/AIDS, Tuberculosis","enrollment":26},{"nctId":"NCT04856644","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2020-01-01","conditions":"Tuberculosis, Pulmonary","enrollment":333},{"nctId":"NCT04176250","phase":"PHASE2","title":"Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Gates Medical Research Institute","startDate":"2020-01-16","conditions":"Pulmonary Tuberculosis","enrollment":93},{"nctId":"NCT03151499","phase":"PHASE1","title":"Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-05-30","conditions":"Healthy","enrollment":15},{"nctId":"NCT04145258","phase":"PHASE3","title":"Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-02-07","conditions":"Tuberculous Meningitis","enrollment":768},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT04694586","phase":"PHASE2","title":"Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide","status":"SUSPENDED","sponsor":"University Hospital, Linkoeping","startDate":"2022-11-30","conditions":"Tuberculosis, Pulmonary","enrollment":40},{"nctId":"NCT03537495","phase":"PHASE2","title":"Pharmacokinetic Study of Linezolid for TB Meningitis","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2021-06-21","conditions":"Tuberculosis, Meningeal, Linezolid","enrollment":36},{"nctId":"NCT03941496","phase":"PHASE1, PHASE2","title":"Azacytidine During Anti-tuberculosis Therapy","status":"WITHDRAWN","sponsor":"Andrew Dinardo","startDate":"2022-10","conditions":"Tuberculosis, Pulmonary","enrollment":""},{"nctId":"NCT02554318","phase":"NA","title":"Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2013-11","conditions":"Pulmonary Tuberculosis, Body Weight Changes, Motor Activity","enrollment":147},{"nctId":"NCT02467608","phase":"PHASE2, PHASE3","title":"Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2012-12-06","conditions":"Pulmonary Tuberculosis","enrollment":557},{"nctId":"NCT01571414","phase":"PHASE1","title":"Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05","conditions":"Tuberculosis","enrollment":52},{"nctId":"NCT02958709","phase":"PHASE1, PHASE2","title":"Optimizing Treatment to Improve TBM Outcomes in Children","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-02-22","conditions":"Tuberculosis, Meningeal","enrollment":38},{"nctId":"NCT02383849","phase":"","title":"IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-08-04","conditions":"Low-Birth-Weight Infant, Tuberculosis, HIV","enrollment":124},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04766307","phase":"PHASE4","title":"A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2016-07-20","conditions":"Tuberculosis, Pulmonary","enrollment":1100},{"nctId":"NCT00925756","phase":"PHASE4","title":"CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2008-10-20","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT00411996","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2006-12","conditions":"HIV Infections, Tuberculosis","enrollment":20},{"nctId":"NCT01138202","phase":"PHASE2","title":"Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-11","conditions":"HIV Infections, Tuberculosis","enrollment":40},{"nctId":"NCT02231229","phase":"PHASE4","title":"Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2014-07-23","conditions":"Tuberculosis","enrollment":204},{"nctId":"NCT03862248","phase":"PHASE3","title":"Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More","status":"WITHDRAWN","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2019-09-30","conditions":"Tuberculosis, Pulmonary","enrollment":""},{"nctId":"NCT01659437","phase":"PHASE2, PHASE3","title":"WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2012-12","conditions":"Mycobacterium Ulcerans Infection","enrollment":310},{"nctId":"NCT03563599","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)","status":"COMPLETED","sponsor":"Qurient Co., Ltd.","startDate":"2018-07-23","conditions":"Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB","enrollment":60},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT00933790","phase":"PHASE3","title":"Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Tuberculosis Research Centre, India","startDate":"2009-09-14","conditions":"HIV Infection, Pulmonary TB","enrollment":331},{"nctId":"NCT03892161","phase":"PHASE1","title":"Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2018-04-12","conditions":"HIV Infections","enrollment":17},{"nctId":"NCT02279875","phase":"PHASE2","title":"A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-11","conditions":"Pulmonary Tuberculosis","enrollment":113},{"nctId":"NCT02457208","phase":"PHASE1","title":"PK Study of Anti-TB Drugs","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-07-07","conditions":"Tuberculosis","enrollment":61},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT03312647","phase":"","title":"Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection","status":"UNKNOWN","sponsor":"Hanyang University","startDate":"2017-06-19","conditions":"Latent Tuberculosis Infection","enrollment":1000},{"nctId":"NCT00669643","phase":"PHASE4","title":"Uniform Multidrug Therapy Regimen for Leprosy Patients","status":"COMPLETED","sponsor":"University of Brasilia","startDate":"2007-02","conditions":"Leprosy","enrollment":859},{"nctId":"NCT02348177","phase":"PHASE4","title":"Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2013-01","conditions":"Acquired Immunodeficiency Syndrome, Tuberculosis","enrollment":96},{"nctId":"NCT01591850","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Healthy Volunteer","enrollment":51},{"nctId":"NCT02313610","phase":"PHASE2","title":"Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2011-04","conditions":"Pulmonary Tuberculosis","enrollment":253},{"nctId":"NCT00370149","phase":"PHASE4","title":"Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children","status":"TERMINATED","sponsor":"Indiana University School of Medicine","startDate":"2006-09","conditions":"Infection Prevention","enrollment":326},{"nctId":"NCT01225640","phase":"PHASE2","title":"PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay","status":"COMPLETED","sponsor":"Sequella, Inc.","startDate":"2011-08","conditions":"Tuberculosis","enrollment":59},{"nctId":"NCT00771498","phase":"PHASE4","title":"An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin","status":"COMPLETED","sponsor":"Oswaldo Cruz Foundation","startDate":"2008-11","conditions":"HIV Infection, Tuberculosis","enrollment":30},{"nctId":"NCT01222338","phase":"PHASE2","title":"Safety and Efficacy of Oral Immunomodulator in Tuberculosis (TB) and TB/HIV Patients","status":"COMPLETED","sponsor":"Lisichansk Regional Tuberculosis Dispensary","startDate":"2010-01","conditions":"Tuberculosis","enrollment":123},{"nctId":"NCT01158755","phase":"PHASE2","title":"Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2010-10","conditions":"Meningitis, Tuberculous, Pharmacokinetics, Pharmacodynamics","enrollment":60},{"nctId":"NCT00321178","phase":"PHASE2, PHASE3","title":"BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANA","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2006-05","conditions":"Buruli Ulcer, Mycobacterium Ulcerans","enrollment":151}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":178,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Metronidazole","Rif"],"phase":"marketed","status":"active","brandName":"Rifampicin (R)","genericName":"Rifampicin (R)","companyName":"University College, London","companyId":"university-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis. Used for Tuberculosis (drug-susceptible and drug-resistant), Leprosy, Atypical mycobacterial infections (MAC, M. marinum).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}